Trial Site Detail

 

Drug:
CB-839 + Talazoparib
Trial:
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Conditions: Solid Tumors
Trial Status:
Recruiting

 

MD Anderson Cancer Center

1505 Holcombe Blvd.     
Houston , TX 77030
USA

 

Principal Investigator:
Funda Meric-Bernstam, MD
Contact:
Contact: Payal Raulji 713-745-2939 pmraulji@mdanderson.org
Activation Status of this Site:
Active
Notes about this Site:
MD Anderson Cancer Center Website:
http://www.mdanderson.org/Cancer_Pro/CS_Resources/display.cfm?id=562561A1-751F-11D4-AEBD00508BDCCE3A&method=displayFull

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.